‘Hesitancy’ will be next snag with vaccinations

NEXT CHALLENGE: Panelists discuss the region’s rollout of the COVID-19 vaccine during the PBN Health Care Summit on April 8. Clockwise from top left is Dr. Karen Tashima, who directs clinical trials for Life­span Corp.; Dr. Kirsten Anderson, from Aetna/CVS Health; moderator PBN Editor Michael Mello; Dr. Ashish Jha, dean of the School of Public Health at Brown University; Christopher Palmieri, CEO and president of Commonwealth Care Alliance; and Peter Marino, CEO of Neighborhood Health Plan of Rhode Island.
NEXT CHALLENGE: Panelists discuss the region’s rollout of the COVID-19 vaccine during the PBN Health Care Summit on April 8. Clockwise from top left is Dr. Karen Tashima, who directs clinical trials for Life­span Corp.; Dr. Kirsten Anderson, from Aetna/CVS Health; moderator PBN Editor Michael Mello; Dr. Ashish Jha, dean of the School of Public Health at Brown University; Christopher Palmieri, CEO and president of Commonwealth Care Alliance; and Peter Marino, CEO of Neighborhood Health Plan of Rhode Island.

Rhode Island will soon hit a tipping point in COVID-19 vaccinations – a point at which there will be more vaccine available than the demand for it, according to public health professionals. And that’s not necessarily a positive development. So-called vaccine hesitancy, the term health officials use to describe reluctance or unwillingness to take a

Already a Subscriber? Log in

To Continue Reading This Article

Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.

Learn More and Become a Subscriber

No posts to display